Insider Selling: Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Sells 5,698 Shares of Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) CEO Todd Harris sold 5,698 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $24.31, for a total value of $138,518.38. Following the completion of the sale, the chief executive officer now directly owns 1,496,729 shares of the company’s stock, valued at $36,385,481.99. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Tyra Biosciences Trading Up 1.5 %

NASDAQ:TYRA opened at $24.36 on Monday. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -14.50 and a beta of 1.01. The business’s fifty day moving average price is $21.29 and its 200 day moving average price is $18.72. Tyra Biosciences, Inc. has a 1-year low of $10.38 and a 1-year high of $25.14.

Tyra Biosciences (NASDAQ:TYRA) last announced its earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.09. Equities analysts forecast that Tyra Biosciences, Inc. will post -1.53 earnings per share for the current year.

Analyst Ratings Changes

TYRA has been the topic of several recent research reports. Wedbush restated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research report on Thursday, August 8th. Oppenheimer lifted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a report on Thursday. Piper Sandler assumed coverage on Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Tyra Biosciences in a research note on Wednesday, July 3rd. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $26.40.

Institutional Trading of Tyra Biosciences

Several large investors have recently made changes to their positions in TYRA. HighVista Strategies LLC bought a new position in Tyra Biosciences in the 2nd quarter worth approximately $257,000. Rhumbline Advisers raised its position in shares of Tyra Biosciences by 12.3% during the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock worth $377,000 after acquiring an additional 2,574 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of Tyra Biosciences by 53.4% during the fourth quarter. Victory Capital Management Inc. now owns 50,220 shares of the company’s stock valued at $696,000 after acquiring an additional 17,490 shares during the period. Bank of New York Mellon Corp boosted its holdings in Tyra Biosciences by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after acquiring an additional 14,352 shares during the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in Tyra Biosciences in the first quarter worth about $977,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.